https://www.marketscreener.com/quote/stock/FRAZIER-LIFESCIENCES-ACQU-147300154/news/Newamsterdam-Pharma-Company-N-V-Doses-First-Patient-in-Phase-3-Tandem-Clinical-Trial-Evaluating-Fix-46152566/?utm_source=telegram&utm_medium=social&utm_campaign=share